Redeye provides its initial take on OEM’s Q1 2025 report, which came in slightly below our estimates...
Sales -12%, adj. EBITA -60% vs. cons, -18% org. growth Consensus to lower '25e-'26e EBITA by 3-5% Sh...
Redeye comments briefly on Insplorion’s Q1 report which was very much in line with our expectations.
Redeye comments on Powercell’s Q1 report which was mainly in line with our expectations.
Redeye was hoping for a bit more in terms of sales, although market conditions were far from ideal.
Vitrolife faces a tough start in 2025, and we expect this to continue during H1 2025.
Q1 sales 3% below our ests. at SEK 207m, for -2.3% org.
Redeye gives its initial take on BONESUPPORT’s Q1 report.
Redeye sees a softer-than-anticipated Q1 report from Stille, with sales and EBIT falling below our f...
Redeye comments on Polygiene Group´s Q1 2025. Polygiene Group delivered positive growth of 18% YoY w...
Enea's net sales rose 7% to SEK214m, beating Redeye Research Estimate (RRe) by 2%, with the network ...
Fiskars Q1 adjusted EBIT of EUR 26.8m came 1% above Modular Finance consensus expectations.
Redeye updates its outlook on Nanologica, continuing to anticipate a considerable sales ramp-up in H...
Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, cur...
Ahead of Taaleri's Q1 report due on 29 April, we revise our estimates to match the new reporting str...
